27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
The model accurately identified dementia subtypes using measures readily available in underrepresented settings, with a similar performance than advanced biomarkers. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Implementation efforts resulted in the adoption of the Care Ecosystem at 28 health systems and eight community-based organizations, including 22 participants in Medicare's Guiding an Improved Dementia Experience (GUIDE) payment model. 5 key findings →
Participants: 22 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Latin America’s diverse genetic landscape provides a unique opportunity to study Alzheimer’s disease (AD) and frontotemporal dementia (FTD). 1 key finding →
Participants: 2,162 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Among 52 participants recruited, 27 were former caregivers, 16 were current caregivers, and nine were persons with dementia; experiences reflected Alzheimer's (n = 18), sporadic Creutzfeldt-Jakob (n = 12), Lewy body (n = 7), and other dementias (n = 15). 5 key findings →
Participants: 18 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In the LA cohort only, higher WMHs load was associated with greater GM atrophy across all groups (HCs, AD, bvFTD), with a specific neurodegenerative pattern involving orbitofrontal, cingulate, and temporal areas. 5 key findings →
Participants: 402 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In bvFTD patients, longer interoceptive-ACWs than controls were observed in the bilateral fronto-temporal and parietal regions. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
"Rapid-type" caregivers (n = 12) had a median age of 59 (range 45-73) years; 6 were female, and 9 were spouses. 5 key findings →
Participants: 12 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
FAB-Ch scores were significantly lower in individuals with dementia compared to controls (p < .001). 5 key findings →
Participants: 288 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
They are often found in middle-aged individuals and are associated with a greater risk of stroke and vascular dementia. 5 key findings →
Participants: 1,072 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Among people with dementia, predicted 1-year mortality was higher among those with hip fracture (35.4%) versus those without hip fracture (14.8%), with similar patterns for pneumonia (49.6% vs. 13.0%). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
People with dementia have complex medical, functional, and social needs and experience highly variable care quality and outcomes across the U.S. health care system. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
VBPs indicate how much 174 countries should be willing to pay. 2 key findings →
Design: modelling Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Plasma glial fibrillary acidic protein (GFAP) has emerged as a promising biomarker of astrocytic reactivity in preclinical Alzheimer´s Disease (AD). 4 key findings →
Participants: 143 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
hexanucleotide repeat expansions (HRE) and WMH in bvFTD patients. bvFTD and svPPA are associated with elevated WMH burden independent of CVRF. 3 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Age-related hearing loss (ARHL) has emerged as a significant and potentially modifiable risk factor for neurodegenerative disorders, including Alzheimer's disease. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Early detection of abnormal neurodegeneration amidst normal cognitive aging is crucial. 1 key finding →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Twenty-six percent of eligible ED users contacted elected for study enrollment. 5 key findings →
Participants: 160 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
As the U.S. population ages, Alzheimer's disease and related dementias (ADRD) cases are increasing, resulting in long wait times for specialist care. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Residence in the most disadvantaged neighborhoods may be associated with lower amyloid pathology in cognitively impaired individuals. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Peruvian GWAS identified Amerindian ancestry specific exonic AD susceptibility variant p.H157Y. This variant has been previously reported as AD marker in Han Chinese populations with extreme effect size, but its rarity and contradictory findings in other groups suggest a potential ancestry‐specific effect. 4 key findings →
Participants: 567 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The results of anonymous surveys conducted among the clinic9s providers are reported as descriptive findings. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Hospice use (2011-2021) for decedents with cancer and dementia by ethnic and racial groups. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
For TabCAT tests, there were no notable floor or ceiling effects, and test scores were associated with age and education as expected. 3 key findings →
Design: cohort study Participants: 563 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
INTRODUCTIONDementia research in sub-Saharan Africa remains limited despite rapid population aging and substantial ancestral, environmental, and vascular diversity. 1 key finding →
Design: longitudinal study Participants: 102 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →